Fraiser Kansteiner

As Donald J. Trump gradually fills out his cabinet, the President-elect's latest pick could bode well for biopharma business development over the next four years.

With a new CEO at the helm, Swiss CDMO Lonza is looking to revivify its business by doubling down on contract manufacturing and jettisoning less profitable areas of its operations.

Following the apparent elimination of a late-stage gene therapy study last week, Swiss drug juggernaut Roche has confirmed that it's axing a hemophilia candidate inherited in its 2019 buyout of Spark Therapeutics.

As Merck and Roche continue to march their respective inflammatory bowel disease (IBD) assets through the clinic, Sanofi and Teva are closing the gap with positive data on their own anti-TL1A antibody duvakitug.

It's the end of an era at Jazz Pharmaceuticals as the drugmaker's cofounder and CEO, Bruce Cozadd, eyes his exit after nearly 22 years with the company—some 15 of which were spent at the helm.

With Novo Nordisk's name already synonymous with treatments for diabetes and obesity, the Danish drugmaker has been making a concerted push to

Looking to significantly bolster its presence across Asia, Indian solid dosage manufacturer ACG has kicked off operations at a massive plant in Thailand.

In a move that follows an increasingly common trend in biopharma M&A, Novartis is shedding sites and staffers from the German cancer biotech it acquired earlier this year.

Christmas has come early for Eli Lilly this year, courtesy of a fresh FDA approval for the Indianapolis drugmaker's obesity star Zepbound.

Undeterred by last year's rejection and the recent approval of a close rival from Pfizer, Novo Nordisk has pushed its once-daily hemophilia injection across the regulatory finish line days before we hit 2025.